Although polyphenols have great pharmacological potential, the main disadvantage is that they have low bioavailability at the desired site. Thus, the use of biocompatible systems for drug delivery is a strategy that is currently gaining great interest. The objective of this study is to evaluate the effect of microencapsulation of caffeic acid and pinocembrin on the antioxidant and antiangiogenic activity of both polyphenols, by the use of nPSi-βCD composite microparticles. For this HUVEC, cells were exposed to H₂O₂ and to treatments with polyphenols in solution and loaded in the composite microparticle. The polyphenols were incorporated into a microparticle using nanoporous silicon, chitosan and a β-cyclodextrin polymer as the biomaterial. The evaluation of the antiangiogenic effect of the treatments with polyphenols in solution and microencapsulated was carried out through functional tests, and the changes in the expression of target genes associated with the antioxidant pathway and angiogenesis was performed through qPCR. The results obtained show that the caffeic acid and pinocembrin have an antioxidant and antiangiogenic activity, both in solution as microencapsulated. In the caffeic acid, a greater biological effect was observed when it was incorporated into the nPSi-βCD composite microparticle. Our results suggest that the nPSi-βCD composite microparticle could be used as an alternative oral drug administration system.

Background and Objectives: Fibromyalgia (FM) is a chronic and complex condition characterized by widespread pain, fatigue, psychological burden, and cognitive impairment, posing significant challenges for treatment. Immersive virtual reality exercise (iVRE) has been proposed as an innovative therapeutic approach to increase adherence, motivation, and multidimensional benefits, but evidence in FM remains limited. This study aimed to evaluate the effects of a six-week iVRE program on cortisol levels, quality of life, cognitive function, and psychological symptoms in women with FM. Materials and Methods: A quasi-experimental pre–post design was conducted with 21 women (mean age 48.1 ± 10.7 years) diagnosed with FM, who completed twelve 30 min sessions of iVRE using Oculus Quest 2™ and the FitXR platform. Outcomes assessed pre- and post-intervention included salivary cortisol (ELISA), quality of life (FIQR), emotional status (DASS-21), and cognitive function (MoCA). Adherence and safety were monitored throughout. Results: The intervention was well tolerated, with no adverse events and 100% adherence. Statistically significant improvements were observed in FIQR scores (p < 0.001, d = 3.54), depression (p < 0.001, d = 1.19), anxiety (p < 0.001, d = 1.39), and stress (p < 0.001, d = 2.28). Cognitive performance improved significantly, with higher MoCA total scores (p < 0.001, d = 1.52) and better outcomes in visuospatial ability, language, and delayed recall domains. No significant changes were detected in salivary cortisol levels (p = 1.000). Conclusions: A six-week iVRE program is safe and feasible, promoting clinically relevant improvements in quality of life, emotional well-being, and cognitive function in women with FM, despite the absence of changes in cortisol. These findings highlight iVRE as a promising complementary therapeutic strategy within multidisciplinary FM management, warranting further controlled studies with larger samples and long-term follow-up to confirm its efficacy and explore underlying mechanisms.

Background: Various tools have been proposed for predicting mortality among patients hospitalized with COVID-19 to improve clinical decision-making, the predictive capacities of which vary in different populations. The objective of this study was to develop a model for predicting mortality among patients hospitalized with COVID-19 during their time in a clinical centre. Methods: This was a retrospective study that included 201 patients hospitalized with COVID-19. Mortality was evaluated with the Kaplan–Meier curve and Cox proportional hazards models. Six models were generated for predicting mortality from laboratory markers and patients’ epidemiological data during their stay in a clinical centre. Results: The model that presented the best predictive power used D-dimer adjusted for C-reactive protein (CRP) and oxygen saturation. The sensitivity (Sn) and specificity (Sp) at 15 days were 75% and 71.9%, respectively. At 30 days, Sn was 75% and Sp was 75.4%. Conclusions: These results allowed us to establish a model for predicting mortality among patients hospitalized with COVID-19 based on D-dimer laboratory biomarkers adjusted for CRP and oxygen saturation. This mortality predictor will allow patients to be identified who require more continuous monitoring and health care.

Background and aims: It is reported that patients with obesity are more frequently hospitalized for COVID-19, and evidence exists that obesity is a risk factor, regardless of other comorbidities. The objective of this study was to evaluate the association of obesity with changes in laboratory biomarkers in hospitalized Chilean patients. Materials and methods: A total of 202 hospitalized patients (71 with obesity and 131 without obesity) with a diagnosis of COVID-19 were included in the study. Demographic, clinical, and laboratory (days 1, 3, 7, 15) data were obtained. We performed a statistical analysis, assuming significance with a value of p < 0.05. Results: Significant differences in chronic respiratory pathology are observed between patients with and without obesity. The inflammatory markers CPR, ferritin, NLR, and PLR are elevated during the evaluated period, while changes in leukocyte populations are present on day 1 (eosinophils) and day 3 (lymphocytes). Finally, a persistent elevation of D-dimer level is observed, presenting significant differences on day 7 between patients with and without obesity. Obesity had a positive correlation with admission to the critical patient unit, invasive mechanical ventilation, and length of hospital stay. Conclusion: Patients with obesity hospitalized for COVID-19 present marked elevations of inflammatory and hemostasis parameters, with a correlation between obesity, changes in laboratory biomarkers, and the risk of adverse clinical outcomes also observed.